Savara Inc
Research Savara Inc (SVRA) on Bullrun: market cap USD 1.15B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSVRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.15B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 37.28M
- Free cash flow-USD 33.10M
Valuation Snapshot
latest market cap is USD 1.15B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 118.84M | -USD 101.06M | n/a | -0.53 | USD 33.18M | USD 29.91M | USD 203.13M |
| FY2024 | USD 0 | -USD 95.88M | -USD 89.11M | n/a | -0.48 | USD 15.13M | USD 26.62M | USD 171.45M |
| FY2023 | n/a | -USD 54.70M | -USD 51.36M | n/a | -0.33 | USD 26.59M | USD 26.35M | USD 140.37M |
| FY2022 | n/a | -USD 38.15M | -USD 34.56M | n/a | -0.25 | USD 52.10M | USD 26.08M | USD 107.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.15B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.23B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 529.34M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 636.10M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 176.77M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 141.41M | n/a | n/a | n/a |
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Savara Inc's market cap?
Savara Inc's market capitalization is USD 1.15B.
What does Savara Inc do?
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.